JP5876652B2 - 転移期前立腺癌を治療する方法 - Google Patents

転移期前立腺癌を治療する方法 Download PDF

Info

Publication number
JP5876652B2
JP5876652B2 JP2010545576A JP2010545576A JP5876652B2 JP 5876652 B2 JP5876652 B2 JP 5876652B2 JP 2010545576 A JP2010545576 A JP 2010545576A JP 2010545576 A JP2010545576 A JP 2010545576A JP 5876652 B2 JP5876652 B2 JP 5876652B2
Authority
JP
Japan
Prior art keywords
degarelix
treatment
prostate cancer
patients
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010545576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511786A5 (https=
JP2011511786A (ja
Inventor
ペルソン，ボ−エリック
Original Assignee
フエリング・インターナシヨナル・センター・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5876652(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by フエリング・インターナシヨナル・センター・エス・アー filed Critical フエリング・インターナシヨナル・センター・エス・アー
Publication of JP2011511786A publication Critical patent/JP2011511786A/ja
Publication of JP2011511786A5 publication Critical patent/JP2011511786A5/ja
Application granted granted Critical
Publication of JP5876652B2 publication Critical patent/JP5876652B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010545576A 2008-02-11 2009-02-10 転移期前立腺癌を治療する方法 Active JP5876652B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
US61/027,741 2008-02-11
EP08250703 2008-02-29
EP08250703.9 2008-02-29
US14795609P 2009-01-28 2009-01-28
US61/147,956 2009-01-28
PCT/IB2009/000370 WO2009101533A1 (en) 2008-02-11 2009-02-10 Treatment of metastatic stage prostate cancer with degarelix

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014087895A Division JP6254042B2 (ja) 2008-02-11 2014-04-22 転移期前立腺癌を治療する方法

Publications (3)

Publication Number Publication Date
JP2011511786A JP2011511786A (ja) 2011-04-14
JP2011511786A5 JP2011511786A5 (https=) 2012-03-22
JP5876652B2 true JP5876652B2 (ja) 2016-03-02

Family

ID=39718285

Family Applications (12)

Application Number Title Priority Date Filing Date
JP2010545576A Active JP5876652B2 (ja) 2008-02-11 2009-02-10 転移期前立腺癌を治療する方法
JP2010545575A Active JP5924866B2 (ja) 2008-02-11 2009-02-10 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP2014051197A Active JP6189234B2 (ja) 2008-02-11 2014-03-14 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP2014087895A Active JP6254042B2 (ja) 2008-02-11 2014-04-22 転移期前立腺癌を治療する方法
JP2016095555A Pending JP2016193910A (ja) 2008-02-11 2016-05-11 転移期前立腺癌を治療する方法
JP2016099437A Pending JP2016216455A (ja) 2008-02-11 2016-05-18 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP2017185676A Active JP6618967B2 (ja) 2008-02-11 2017-09-27 転移期前立腺癌を治療する方法
JP2022109616A Active JP7400029B2 (ja) 2008-02-11 2022-07-07 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP2022142833A Pending JP2022184898A (ja) 2008-02-11 2022-09-08 転移期前立腺癌を治療する方法
JP2023206150A Pending JP2024028869A (ja) 2008-02-11 2023-12-06 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP2025106071A Pending JP2025160167A (ja) 2008-02-11 2025-06-24 転移期前立腺癌を治療する方法
JP2025194876A Pending JP2026027448A (ja) 2008-02-11 2025-11-14 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法

Family Applications After (11)

Application Number Title Priority Date Filing Date
JP2010545575A Active JP5924866B2 (ja) 2008-02-11 2009-02-10 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP2014051197A Active JP6189234B2 (ja) 2008-02-11 2014-03-14 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP2014087895A Active JP6254042B2 (ja) 2008-02-11 2014-04-22 転移期前立腺癌を治療する方法
JP2016095555A Pending JP2016193910A (ja) 2008-02-11 2016-05-11 転移期前立腺癌を治療する方法
JP2016099437A Pending JP2016216455A (ja) 2008-02-11 2016-05-18 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP2017185676A Active JP6618967B2 (ja) 2008-02-11 2017-09-27 転移期前立腺癌を治療する方法
JP2022109616A Active JP7400029B2 (ja) 2008-02-11 2022-07-07 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP2022142833A Pending JP2022184898A (ja) 2008-02-11 2022-09-08 転移期前立腺癌を治療する方法
JP2023206150A Pending JP2024028869A (ja) 2008-02-11 2023-12-06 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法
JP2025106071A Pending JP2025160167A (ja) 2008-02-11 2025-06-24 転移期前立腺癌を治療する方法
JP2025194876A Pending JP2026027448A (ja) 2008-02-11 2025-11-14 Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法

Country Status (25)

Country Link
US (17) US8841081B2 (https=)
EP (7) EP2650012B1 (https=)
JP (12) JP5876652B2 (https=)
KR (8) KR101542480B1 (https=)
CN (4) CN103990107A (https=)
AU (2) AU2009213751B2 (https=)
BR (2) BRPI0908127A2 (https=)
CA (3) CA2714445C (https=)
CY (3) CY1115561T1 (https=)
DK (3) DK2249859T3 (https=)
EA (4) EA036695B1 (https=)
ES (3) ES2532709T3 (https=)
HK (1) HK1198243A1 (https=)
HR (3) HRP20140665T1 (https=)
IL (3) IL207295A (https=)
JO (1) JOP20090061B1 (https=)
MX (2) MX2010008816A (https=)
NZ (4) NZ587057A (https=)
PL (3) PL2249859T3 (https=)
PT (3) PT2249859E (https=)
RU (2) RU2504394C2 (https=)
SI (3) SI2249859T1 (https=)
TW (2) TWI442932B (https=)
WO (2) WO2009101530A1 (https=)
ZA (1) ZA201005697B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016193910A (ja) * 2008-02-11 2016-11-17 フエリング・インターナシヨナル・センター・エス・アー 転移期前立腺癌を治療する方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
PT2632934T (pt) 2010-10-27 2017-01-06 Ferring Bv Processo para o fabrico de degarelix e seus intermediários
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
BR112013023050A8 (pt) * 2011-03-09 2018-09-25 G Pestell Richard antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
AU2013262977A1 (en) 2012-05-14 2015-01-22 Prostagene, Llc Using modulators of CCR5 for treating cancer
SG11201407679PA (en) 2012-06-01 2014-12-30 Ferring Bv Manufacture of degarelix
SG11201501870RA (en) 2012-09-26 2015-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AR092707A1 (es) 2012-09-28 2015-04-29 Takeda Pharmaceuticals Co Metodo de produccion de derivado de tienopirimidina
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
WO2014186608A1 (en) * 2013-05-15 2014-11-20 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
EP3185881B1 (en) * 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
JP6941565B2 (ja) * 2015-05-12 2021-09-29 ドレクセル ユニバーシティ がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
MA46361A (fr) 2016-09-30 2021-03-31 Myovant Sciences Gmbh Traitement du cancer de la prostate
JP6990717B2 (ja) * 2017-01-30 2022-02-03 アンテヴ リミテッド 少なくとも１種のｇｎｒｈアンタゴニストを含む組成物
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN112261942A (zh) 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
JP2021532160A (ja) * 2018-08-01 2021-11-25 アッヴィ・インコーポレイテッド エラゴリックスに関する投与計画
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494B (zh) * 2023-03-02 2024-07-09 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ZA735680B (en) * 1972-09-21 1974-07-31 Hoffmann La Roche Polypeptides
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE69214818T2 (de) 1991-04-25 1997-02-27 Romano S.-Cergue Deghenghi LHRH-Antagonisten
DE69330107T3 (de) 1992-02-12 2004-12-30 Daikyo Gomu Seiko, Ltd. Medizinisches Gerät
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
JP3688381B2 (ja) 1995-03-10 2005-08-24 株式会社東芝 光ディスク原盤露光装置
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
WO1999026964A1 (en) 1997-11-20 1999-06-03 Ortho-Mcneil Pharmaceutical, Inc. LIQUID PHASE PROCESS FOR THE PREPARATION OF GnRH PEPTIDES
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
CA2336879C (en) 1998-07-20 2010-06-01 Peptech Limited Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients
CN1443195A (zh) * 2000-03-14 2003-09-17 赞塔里斯股份公司 新型lhrh拮抗剂,其制备方法和药物用途
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
EP2277542B1 (en) * 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
GB0117057D0 (en) 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
RS52966B (sr) 2002-09-27 2014-02-28 Zentaris Gmbh Oblik za terapijsku primenu aktivnih peptida sa produženim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
WO2009090189A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
US8105292B2 (en) * 2008-02-11 2012-01-31 Safety Syringes, Inc. Reconstitution means for safety device
KR101621725B1 (ko) 2009-04-24 2016-05-17 폴리펩타이드 라보라토리즈 에이/에스 데가렐릭스의 제조 방법
EP2424503B1 (en) 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
IT1399892B1 (it) 2010-03-15 2013-05-09 Spi Tecno Srl Sistema per l illuminazione pubblica
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
PT2632934T (pt) 2010-10-27 2017-01-06 Ferring Bv Processo para o fabrico de degarelix e seus intermediários
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
EP2731607B1 (en) 2011-07-15 2017-10-11 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered
SG11201407679PA (en) 2012-06-01 2014-12-30 Ferring Bv Manufacture of degarelix

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016193910A (ja) * 2008-02-11 2016-11-17 フエリング・インターナシヨナル・センター・エス・アー 転移期前立腺癌を治療する方法
JP2018039814A (ja) * 2008-02-11 2018-03-15 フエリング・インターナシヨナル・センター・エス・アー 転移期前立腺癌を治療する方法

Also Published As

Publication number Publication date
PT2505204E (pt) 2015-03-26
TWI539959B (zh) 2016-07-01
EA200901074A1 (ru) 2010-04-30
EP2249859A1 (en) 2010-11-17
CN101939020B (zh) 2012-12-26
HRP20150290T1 (hr) 2015-04-10
JP2022133426A (ja) 2022-09-13
AU2009213748B9 (en) 2014-05-22
EP2249859B1 (en) 2014-04-23
EP2505204A2 (en) 2012-10-03
WO2009101533A1 (en) 2009-08-20
US20090203622A1 (en) 2009-08-13
KR20230088848A (ko) 2023-06-20
JP6618967B2 (ja) 2019-12-11
CA2714444A1 (en) 2009-08-20
PL2249859T3 (pl) 2014-10-31
KR20220009504A (ko) 2022-01-24
KR101542480B1 (ko) 2015-08-07
CY1116341T1 (el) 2017-02-08
PL2650012T3 (pl) 2015-08-31
EP2505204B1 (en) 2014-12-24
US12533387B2 (en) 2026-01-27
RU2504393C2 (ru) 2014-01-20
US20190167755A1 (en) 2019-06-06
US20220218783A1 (en) 2022-07-14
EP2799085A1 (en) 2014-11-05
EA201300742A1 (ru) 2014-02-28
AU2009213751B2 (en) 2014-09-25
US20090203623A1 (en) 2009-08-13
US9415085B2 (en) 2016-08-16
CN101998861A (zh) 2011-03-30
US12514898B2 (en) 2026-01-06
US20250134948A1 (en) 2025-05-01
CY1115561T1 (el) 2017-01-04
US10729739B2 (en) 2020-08-04
JOP20090061B1 (ar) 2021-08-17
JP2016216455A (ja) 2016-12-22
US20240316142A1 (en) 2024-09-26
KR20250028541A (ko) 2025-02-28
EP4257197A3 (en) 2023-11-29
JP2014167009A (ja) 2014-09-11
JP5924866B2 (ja) 2016-05-25
EP2249858A1 (en) 2010-11-17
KR20100123714A (ko) 2010-11-24
JP2016193910A (ja) 2016-11-17
PL2505204T3 (pl) 2015-05-29
EA026521B1 (ru) 2017-04-28
KR20150091543A (ko) 2015-08-11
NZ587088A (en) 2012-12-21
US10973870B2 (en) 2021-04-13
US20220323538A1 (en) 2022-10-13
ES2479441T3 (es) 2014-07-24
JP6254042B2 (ja) 2017-12-27
IL223124A0 (en) 2012-12-31
RU2504394C2 (ru) 2014-01-20
US9877999B2 (en) 2018-01-30
US20170035833A1 (en) 2017-02-09
EA201300741A1 (ru) 2014-02-28
EP2650012A1 (en) 2013-10-16
ZA201005697B (en) 2014-01-24
CN107412726A (zh) 2017-12-01
AU2009213751A1 (en) 2009-08-20
HK1145011A1 (en) 2011-03-25
HRP20150633T1 (hr) 2015-07-31
US20220031801A1 (en) 2022-02-03
EA036695B1 (ru) 2020-12-09
KR20140130757A (ko) 2014-11-11
PT2650012E (pt) 2015-06-30
US10695398B2 (en) 2020-06-30
BRPI0908127A2 (pt) 2015-08-04
KR20100126362A (ko) 2010-12-01
DK2505204T3 (da) 2015-03-16
US20220226422A1 (en) 2022-07-21
WO2009101530A1 (en) 2009-08-20
EA020543B1 (ru) 2014-12-30
JP2024028869A (ja) 2024-03-05
US9579359B2 (en) 2017-02-28
CN101939020A (zh) 2011-01-05
MX2010008816A (es) 2010-09-07
US8841081B2 (en) 2014-09-23
SI2505204T1 (sl) 2015-04-30
EP2650012B1 (en) 2015-03-25
SI2249859T1 (sl) 2014-08-29
CN103990107A (zh) 2014-08-20
US20130029910A1 (en) 2013-01-31
JP2025160167A (ja) 2025-10-22
US20200237854A1 (en) 2020-07-30
RU2010133481A (ru) 2012-03-20
NZ603958A (en) 2013-03-28
ES2540235T3 (es) 2015-07-09
IL207400A (en) 2014-12-31
US20140349935A1 (en) 2014-11-27
CA2714445C (en) 2018-01-16
NZ603932A (en) 2014-04-30
JP6189234B2 (ja) 2017-08-30
EP2505204A3 (en) 2013-01-09
IL207295A0 (en) 2010-12-30
US20210128673A1 (en) 2021-05-06
TW200938218A (en) 2009-09-16
JP2011511785A (ja) 2011-04-14
HK1176552A1 (en) 2013-08-02
JP2011511786A (ja) 2011-04-14
PT2249859E (pt) 2014-07-31
EP4257197A2 (en) 2023-10-11
HK1190912A1 (en) 2014-07-18
EA017582B1 (ru) 2013-01-30
US20220218782A1 (en) 2022-07-14
US11826397B2 (en) 2023-11-28
TW200938217A (en) 2009-09-16
JP7400029B2 (ja) 2023-12-18
CA3235099A1 (en) 2009-08-20
US20170290879A1 (en) 2017-10-12
US20140113870A1 (en) 2014-04-24
ES2532709T3 (es) 2015-03-31
EP3360565A1 (en) 2018-08-15
JP2022184898A (ja) 2022-12-13
IL207400A0 (en) 2010-12-30
HRP20140665T1 (hr) 2014-10-10
IL207295A (en) 2015-03-31
TWI442932B (zh) 2014-07-01
RU2010133480A (ru) 2012-03-20
NZ587057A (en) 2012-12-21
CY1116289T1 (el) 2017-02-08
AU2009213748B2 (en) 2014-03-13
HK1198243A1 (en) 2015-03-20
CA2714445A1 (en) 2009-08-20
MX2010008817A (es) 2010-09-09
AU2009213748A1 (en) 2009-08-20
DK2249859T3 (da) 2014-06-02
US11766468B2 (en) 2023-09-26
DK2650012T3 (da) 2015-06-15
JP2026027448A (ja) 2026-02-18
BRPI0908129A2 (pt) 2015-08-04
JP2018039814A (ja) 2018-03-15
KR20180118830A (ko) 2018-10-31
SI2650012T1 (sl) 2015-06-30
EA200901075A1 (ru) 2010-04-30
JP2014141505A (ja) 2014-08-07

Similar Documents

Publication Publication Date Title
JP6618967B2 (ja) 転移期前立腺癌を治療する方法
JP7186748B2 (ja) 転移期前立腺癌を治療する方法
HK1190912B (en) Treatment of metastatic stage prostate cancer with degarelix
KR20240037954A (ko) 니라파립을 이용한 전이성 거세-저항성 전립선암의 치료
JP2019218360A (ja) Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130925

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140425

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140530

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160122

R150 Certificate of patent or registration of utility model

Ref document number: 5876652

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250